Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu QV, Torkelson A, Kirchmeier DR, Chutnik A, Pender BS, Sorror ML, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green DJ, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: till bg. Blood Adv. 2024 Dec 3:bloodadvances.2024014455. doi: 10.1182/bloodadvances.2024014455. Online ahead of print. Blood Adv. 2024. PMID: 39626349
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Smith MR, Jegede OA, Martin P, Till BG, Parekh SS, Yang DT, Hsi ED, Witzig T, Dave S, Scott D, Hanson C, Kostakoglu Shields L, Abdel-Samad N, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum KA, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little RF, Friedberg JW, Leonard JP, Kahl BS. Smith MR, et al. Among authors: till bg. Blood. 2024 Sep 5;144(10):1083-1092. doi: 10.1182/blood.2024023962. Blood. 2024. PMID: 38820500 Clinical Trial.
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M. Krakow EF, et al. Among authors: till bg. Blood. 2024 Sep 5;144(10):1069-1082. doi: 10.1182/blood.2024024105. Blood. 2024. PMID: 38683966 Clinical Trial.
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Banerjee R, Poh C, Hirayama AV, Gauthier J, Cassaday RD, Shadman M, Cowan AJ, Till BG, Green DJ, Kiem HP, Gopal AK, Maloney DG. Banerjee R, et al. Among authors: till bg. Blood Adv. 2024 Feb 27;8(4):895-898. doi: 10.1182/bloodadvances.2023012336. Blood Adv. 2024. PMID: 38197942 Free PMC article. No abstract available.
73 results